Two formats of semaglutide are now competing in the weight loss market following the approval of oral semaglutide.

1 report, 1 independent Updated Aug 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market. All 2 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

API issues are affecting the production of semaglutide products involving Torrent Pharmaceuticals and Dr. Reddy’s Laboratories.Sep 15

Coverage

Newest first; wire copies grouped

Aug 17augustafreepress.com